乳酸菌阴道胶囊联合重组人干扰素α-2b阴道制剂治疗高危型HPV有效性和安全性的Meta分析  

Effectiveness and safety of lacidophilin vaginal capsules combined with recombinant human interferonα-2b vaginal preparation in the treatment of high-risk HPV infection:a Meta-analysis

作　　者：闫瑞 郑盈盈[2] 何艳妮 王皎 YAN Rui;ZHENG Yingying;HE Yanni;WANG Jiao(Department of Pharmacy,Xi′an International Medical Center Hospital,Xi′an 710100,China;不详)

机构地区：[1]西安国际医学中心医院药学部,西安市710100 [2]河北医科大学第三医院药剂科,石家庄市050000

出　　处：《临床合理用药》2025年第9期31-35,39,共6页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的基于Meta分析评价乳酸菌阴道胶囊联合重组人干扰素α-2b阴道制剂治疗高危型人乳头状瘤病毒(HPV)感染的有效性及安全性。方法计算机检索中国生物医学文献数据库、中国知网、万方数据知识服务平台、维普网及PubMed、Web of Science、Embase上公开发表的乳酸菌阴道胶囊联合重组人干扰素α-2b阴道制剂治疗高危型HPV感染的随机对照试验,文献检索时限为建库至2023年9月。对照组单用重组人干扰素α-2b阴道制剂治疗,试验组采用乳酸菌阴道胶囊联合重组人干扰素α-2b阴道制剂治疗,疗程均为3个月。根据Cochrane系统评价员手册提供的文献偏倚风险评估工具进行文献质量评价,采用RevMan 5.3软件对纳入文献进行Meta分析。结果最终纳入15篇文献,共包含10175例患者,其中试验组5088例,对照组5087例。Meta分析结果显示:试验组有效率高于对照组[OR=2.79,95%CI(2.51,3.11),P<0.00001];试验组IL-4[MD=2.39,95%CI(1.95,2.83)]低于对照组(P<0.00001),IL-12[MD=2.34,95%CI(1.99,2.70)]、IFN-γ[MD=2.56,95%CI(1.86,3.26)]高于对照组(P<0.00001);试验组阴道分泌物pH值低于对照组[MD=-0.45,95%CI(-0.63,-0.27),P<0.00001];2组不良反应发生率比较,差异无统计学意义[OR=1.65,95%CI(0.52,5.22),P=0.39]。结论乳酸菌阴道胶囊联合重组人干扰素α-2b阴道制剂治疗高危型HPV具有良好的疗效和安全性。Objective To evaluate the effectiveness and safety of lacidophilin vaginal capsules combined with recombinant human interferonα-2b vaginal preparation in the treatment of high-risk HPV infection by Meta-analysis method.Methods Randomized controlled trials about high-risk HPV infection treated with lacidophilin vaginal capsules combined with recombinant human interferonα-2b vaginal preparation were retrieved from databases such as CBMdisc,CNKI,WanFang Data,VIP and PubMed,Web of Science,Embase,the retrieval time limit was until September 2023.Patients in the control group were given recombinant human interferonα-2b vaginal preparation,and patients in the experimental group were given lacidophilin vaginal capsules combined with recombinant human interferonα-2b vaginal preparation,both groups were treated for 3 months.Literature quality was evaluated according to the literature bias risk assessment tool provided by Cochrane system evaluator′s manual,and the included literature were Meta-analyzed by RevMan 5.3 software.Results A total of 15 literature included in the Meta-analysis,included 10175 cases,and 5088 cases for the experimental group,5087 for the control group.Meta-analysis results showed that,the experimental group of effect rate was higher than that in the control group[OR=2.79,95%CI(2.51,3.11),P<0.00001];The experimental group of IL-4[MD=2.39,95%CI(1.95,2.83)]was lower than that in the control group(P<0.00001),IL-12[MD=2.34,95%CI(1.99,2.70)]and IFN-γ[MD=2.56,95%CI(1.86,3.26)]were higher than those in the control group(P<0.00001);Vaginal secretion pH value in the experimental group was lower than that in the control group[MD=-0.45,95%CI(-0.63,-0.27),P<0.00001];There was no significant difference of incidence of adverse reactions between the two groups[OR=1.65,95%CI(0.52,5.22),P=0.39].Conclusion Lacidophilin vaginal capsules combined with recombinant human interferonα-2b vaginal preparation has good efficacy and safety in the treatment of high-risk HPV infection.

关 键 词：人乳头状瘤病毒感染 高危型 乳酸菌阴道胶囊 重组人干扰素Α-2B 有效性 安全性 荟萃分析 

分 类 号：R73[医药卫生—肿瘤]